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Abstract: Background: In Norway, low-nitrosamine smokeless tobacco (snus) is allowed 
to compete with cigarettes for market share. We aimed to study how the availability of 
snus influenced overall tobacco consumption, smoking initiation and smoking cessation. 
We discuss whether the Norwegian experience with snus can have any transfer value for  
e-cigarettes. Methods: We analysed consumption data from registered and unregistered 
supply sources of tobacco. We calculated quit-smoking ratios across snus use status in nine 
datasets comprising a total of 19,269 ever-smokers. Trends in snus use and smoking were 
derived from time-series of annual; cross-sectional; nationally representative surveys for 
the period 1985–2013. Results: The market share for snus increased from 4% in 1985 to 
28% in 2012, but overall tobacco consumption decreased by 20.3% over this same period. 
Snus was the most common method for smoking cessation. Compared with smokers with 
no experience of using snus, the quit ratio for smoking was significantly higher for daily 
snus users in seven of the nine datasets analysed. Among young male adults, the 
prevalence of smoking (daily + occasional) was reduced from 50% in 1985 to 21% in 
2013. Over the same period, use of snus increased from 9% to 33%. This negative 
correlation (r = −0.900, p < 0.001) was also observed among young females (r = −0.811,  
p < 0.001), but the trend shift in tobacco preferences occurred some years later. Conclusions: 
The experience with snus in Norway might indicate what will happen when alternative 
nicotine products––are allowed to compete with cigarettes in the nicotine market. 
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1. Introduction 
The long-time availability of low-nitrosamine smokeless tobacco (snus) in some Scandinavian 
countries, including Norway and Sweden, may serve as an example of what could happen on the 
nicotine market if a low-risk nicotine/tobacco product outside the pharmacological product arsenal 
(such as e-cigarettes) is allowed to compete with cigarettes. Like e-cigarettes [1], snus is perceived as a 
less risky alternative to cigarettes [2], but scientists have assessed the relative risk between snus and 
cigarettes to be even greater than is generally perceived [3,4]. In the US, snus has typically been 
marketed to smokers as an expedient method for uptake of nicotine in no-smoking areas, as well as a 
method to quit or reduce the consumption of cigarettes [5]. In Norway and Sweden, all tobacco 
advertising has been banned since the mid-1970s. Hence, the uptake of snus is not driven by 
marketing, but takes place in an epistemological climate where smokers and non-smokers tend to 
overstate the health risk from snus compared with that from cigarettes [2,6]. Moreover, the 
Scandinavian health authorities have warned smokers against all kinds of snus use, even as a method 
for smoking cessation [7]. The typical message has been that snus is not a safe alternative to cigarettes. 
Thus, the competitive condition for snus in Norway and Sweden has been quite similar to the 
present market situation for e-cigarettes in the EU: the Tobacco Product Directive aims to restrict  
e-cigarette advertising to a minimum [8], and the health authorities in most countries have been 
opposed to recommending e-cigarettes for smoking cessation [9]. 
Among health authorities, and in particular within the tobacco control community, there is a 
concern that nicotine products like snus and e-cigarettes will increase the overall use of 
tobacco/nicotine, recruit non-smokers who otherwise would have stayed nicotine abstinent, delay 
cessation among cigarette smokers and lead to multi-product use, and thus jeopardize the potential role 
these products could play in tobacco harm reduction [10–13]. Representatives of the scientific 
community [14,15] have therefore put up a research agenda to assess these and other concerns, and 
because they function as a natural laboratory for observations on snus use, research from Norway and 
Sweden has been of particular interest. 
The extent and nature of the impact on public health of making snus/e-cigarettes available in new 
markets will to a large extent depend on two factors: (1) the relative risk of snus/e-cigarette use 
compared with cigarette smoking, and (2) the relative uptake and patterns of use of snus/e-cigarettes 
by smokers and non-smokers. In contrast to e-cigarettes—where the risk estimates until now have been 
based on studies of the chemical analysis of the e-liquid and the exhaled vapour using animal studies, 
on analysis of acute physiological effects in humans and on self-reports from users [9]—the risk 
estimates for snus use can also be established from long-term epidemiological data on tobacco related 
diseases such as cardiovascular disease [16], cancers and respiratory diseases [17]. 
Nutt et al. [4] used a multi-criteria decision analysis model to assess the relative importance of 
different types of harm related to the use of nicotine-containing products, and concluded that snus only 
caused 5% as much harm as cigarettes. This was consistent with an estimate put forward by Levy et al. [3], 
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who assessed the relative risk applying a Delphi design. Given the medical consensus that snus is 
approximately 90%–95% less harmful than smoking, the overall effect from snus on public health will 
then be driven by the balance between its beneficial effect on smoking prevalence and its adverse 
effects on overall prevalence of tobacco use. With this background, the aim of this article is to 
illustrate how the availability of snus has: (1) influenced the total tobacco consumption in Norway 
through its role in (2) smoking initiation and (3) smoking cessation. We will then discuss whether the 
Norwegian experience of allowing snus to compete with cigarettes can have a transfer value for the 
entrance of e-cigarettes into the nicotine market. 
2. Methods 
2.1. Overall Tobacco Consumption 
Domestic annual sales of tobacco have been recorded by the Norwegian Directorate of Customs and 
Excise. Sales of snus and tobacco for hand-rolled cigarettes have been reported by weight, while 
manufactured cigarettes were converted to weight from the registered number sold (one cigarette 
equals one gram). Estimates of the magnitude of border trade and travellers’ tobacco imports [18,19] 
were added to the registered sales. To make consumption data more robust in Figure 1, the means for two 
three-year periods (1984–1986 and 2010–2013) were compared. To correct for population growth over this 
period, the total annual consumption was divided by the number of persons above 15 years of age. 
Figure 1. Average annual total tobacco consumption per capita (15+ years) and relative 
market share of cigarettes and snus in Norway for the periods 1984–1986 and 2010–2012. 
Source: Norwegian Directorate of Customs and Excise and Norwegian Institute for Alcohol and Drug Research. 
2.2. Use of Snus in Quit-Smoking Attempts 
The study population in Figure 2 included 1830 people who had ever been daily smokers of both 
genders in the age group 15–50 years. The subjects were identified from a data pool from yearly 
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representative surveys of tobacco behaviour carried out by Statistics Norway by telephone for the 
years 2007–2013, and included 4887 respondents in total. The mean response rate for the period was 
67%. The sampling procedures for these surveys have been described previously [6]. Former daily 
smokers (N = 997) and current daily smokers who reported an attempt to quit smoking (N = 639) were 
asked: “Did you use some of these methods when you last tried to quit smoking (multiple answers 
possible)?” Response categories were nicotine gum/nicotine patch, snus, Zyban (Bupropion)/Champix 
(Vareniclin) and “calling the quit line”. 
Figure 2. Methods used (alone or in combination) in smoking cessation by Norwegian 
current (failed quitters) and former daily smokers. Pooled data for 2007–2013. 
 
Source: Statistics Norway and Norwegian Institute for Alcohol and Drug Research. 
2.3. Quit Ratio for Smoking 
The quit ratio for smoking is an expression of the number of former daily smokers as a proportion 
of the total number of people who have ever smoked daily in a population. It is a statistical measure of 
smoking cessation activity that is recommended for use in tobacco behaviour research [20]. To identify 
significant differences in the quit ratio for smoking between daily snus users and people who have 
never used snus, 95% confidence intervals and p-values were calculated and are shown in Table 1. 
The material and methods for Surveys 1–7 in Table 1 have been described previously [21]. As snus 
use until recently has been a predominantly male phenomenon in Norway, no gender-specific results 
were presented in those surveys. Table 1 includes observations from two recent surveys (Surveys 8 and 9 
in Table 1 (ܳݑ݅ݐ	ݎܽݐ݅݋ = ୊୭୰୫ୣ୰	ୱ୫୭୩ୣ୰ୱ	୶	ଵ଴଴୉୴ୣ୰	ୱ୫୭୩ୣ୰ୱ )). In these samples, sufficient females were using snus to 
allow gender-specific results. The study population in Survey 8 is identical to the data pool used for 
the construction of Figure 2 (see above). The study population in Survey 9 included 5813 smokers and 
former smokers of both genders in the age group 15–80 years surveyed in 2009, 2011 and 2013 in the 
33.8
8
20.9
15.1 14.6 14.8
4.6 4.4 4.5
2.2 2.1 2.1
0
5
10
15
20
25
30
35
Men Women Total
%
Snus
Gum/patch
Zyban/Champix
Quit-line
Int. J. Environ. Res. Public Health 2014, 11 11709 
 
 
 
Norwegian Monitor Survey by IPSOS/Synovate. The sampling procedures for this national 
representative survey have been described previously [22]. 
Table 1. Unadjusted quit ratio for daily smoking (with 95% confidence intervals) 
according to snus use status in nine Norwegian surveys comprising 14,761 male and 4508 
female ever-smokers. 
Survey Year 
Number of 
Ever-Smokers 
Age Group Daily Snus User Never Used Snus p-value 
Males 
1 2003–2008 3604 16–74 80.4 (74.9–85.9) 51.9 (50.1–53.7) < 0.001 
2 2007 423 16–20 54.8 (45.2–64.9) 22.9 (17.4–28.4) < 0.001 
3 2006 458 19–30 81.1 (68.5–93.7) 62.7 (56.9–68.4) 0.010 
4 2007 2016 15–91 61.6 (53.5–69.7) 52.5 (50.2–54.8) 0.035 
5 2006 729 21–30 75.4 (65.2–85.6) 44.9 (40.2–49.6) < 0.001 
6 2006 639 21–30 89.7 (81.9–97.5) 50.0 (45.1–54.9) < 0.001 
7 2007 2572 20–50 72.7 (81.9–97.5) 43.3 (40.6–46.0) < 0.001 
8 2009–2013 1543 15–74 80.8 (75.4–86.2) 55.7 (52.9–58.5) < 0.001 
9 2009–2013 2777 15–80 74,6 (69.8–79.4) 65.5 (63.6–67.5) < 0.001 
Total -- 14,761 Weighted mean 74.8 (72.8–76.8) 52.3 (51.4–53.2) < 0.001 
Females 
8 2009–13 1472 15–74 85.7 (75.0–95.2) 52.0 (49.4–54.6) < 0.001 
9 2009–13 3036 15–80 74.8 (65.8–83.8) 61.6 (59.8–63.4) < 0.001 
Total -- 4508 Weighted mean 78.4 (71.5–85.3) 56.1 (54.6–57.6) < 0.001 
2.4. Smoking Initiation 
As the initiation of cigarette smoking is negligible after the age of 30 years, the prevalence of 
smokers (daily and occasional) in the age group 15–30 years was used as a proxy for smoking  
uptake [20]. Data for this age group were derived from a subset sample of the yearly cross-sectional 
surveys carried out by Statistics Norway, described in connection with the construction of Figure 2. 
Trend estimates for cigarette smoking and snus use in Figure 3 were based on three-year moving 
averages for the period 1985–2013. 
3. Results 
The annual overall per capita (15+ years) consumption of tobacco was 2065 grams for the years  
1984–1986. In this period, 96% of the tobacco was consumed as cigarettes (manufactured or roll-your-
own), while the market share for snus was only 4%. In the period 2010–2012 the market share for snus 
had increased to 28%, while cigarettes comprised 72% of the tobacco market. Over these three decades, 
the overall consumption of tobacco in Norway (registered + unregistered) declined by 20.3% to 1646 
grams per capita in 2010–2012. 
Among Norwegian ever-daily smokers who had used a specific method to quit smoking, snus was 
the most common (20.9%), followed by pharmacological nicotine products (14.8%) (Figure 2). The 
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use of snus to quit smoking was particularly prevalent among male quitters (33.8%), while 
pharmacological nicotine was the most common method among females (14.6%). 
Figure 3. Use (daily and occasional) of snus (blue line) and cigarettes (red line) by 
Norwegian males and females in the age group 16–30 years for the period 1985–2013.  
Three-year moving averages. 
 
Source: Statistics Norway and Norwegian Institute for Alcohol and Drug Research. 
Compared with smokers with no experience of using snus, the quit ratio for smoking among males 
was significantly higher for daily snus users in seven of the nine datasets in Table 1. The weighted mean 
for quit-smoking ratios across all datasets was 74.8 (CI 72.8–76.8) among male daily snus users and  
52.3 (CI 51.4–53.2) among male non-users of snus. Among females, the same difference in the quit ratio 
for smoking was observed between daily users [78.4 (CI 71.5–85.3)] and non-users of snus  
[56.1 (54.6–57.6)]. 
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Among young male adults, the prevalence of smoking (daily + occasional) decreased from 50% in 
1985 to 21% in 2013. Over the same period, the prevalence of snus use increased from 9% to 33%. 
Around 2008, snus surpassed cigarettes as the most popular nicotine product. The negative correlation 
between snus use and cigarette smoking among males in this age group (r = −0.900, p < 0.001) was 
also observed among females (r = −0.811, p < 0.001). However, compared with that of males, the 
trend shift in tobacco preferences among women seems to have occurred some years later. 
4. Discussion 
The introduction of low-nitrosamine snus to the nicotine market in the 1990s was followed by an 
increase in snus use. This was first observed among men, but has recently also occurred in women. 
However, the increased use of snus has not led to an increase in overall tobacco consumption, as sales 
of cigarettes have decreased (Figure 1). Three observations lend support to the hypothesis that the 
strong inverse association between snus use and cigarette smoking might be causal. 
First, snus seems to play a significant role in smoking cessation. Use of snus is reported by  
ever-smokers to be the preferred method for quitting (Figure 2), and in several studies from  
Norway [23,24] and Sweden [25–27] former smokers are seen to make up the largest segment of snus 
users. Moreover, daily snus use seems to be associated with particularly high quit rates for smoking 
(Table 1), as also observed in studies from Sweden [25–32]. Several randomized controlled trials have 
also demonstrated that use of smokeless tobacco increases the likelihood of quitting smoking [33–39]. 
Not only does snus surpass the use of pharmacological nicotine products in quit-smoking attempts, 
some studies also indicate that snus might be more effective than pharmacological nicotine products in 
smoking cessation [23,40]. The enhanced effect from snus over medicinal nicotine products (efficacy) 
combined with the high acceptance of snus in smoking cessation implies that the impact on smoking 
abstinence at the population level (effectiveness) is much higher for snus than for other products. 
A second mechanism for a causal relationship between increased market share for snus and the 
reduced market share for cigarettes could be that snus attracts tobacco-prone youth who otherwise 
would have started to smoke. Of course, we do not know the counterfactual—what the rate of decline 
in smoking among youth would have been without the availability of snus over the same time frame. 
However, our hypothesis of a relationship is supported because a large segment of the young snus 
users have characteristics that usually predict uptake of cigarette smoking [41–43]. Moreover, the 
hypothesis is also supported by the simultaneous trend shift for smoking and snus use among young 
adults, and the fact that this has occurred in both sexes at different times (Figure 3). These coincidental 
trend shifts in tobacco preferences haves also been observed in other datasets in Norway [41,44,45]. 
As far as we know, the rapidity of the decline in smoking among youth in Norway has not been 
matched in any other Western country. 
A third mechanism through which snus may have contributed to a decrease in cigarette 
consumption is that snus is used by many smokers to reduce smoking intensity or as a nicotine 
replacement where smoking is prohibited [21,23,24]. In Norway, dual users of snus and cigarettes have 
a weekly consumption of cigarettes that is 40% below that of exclusive smokers [24]. However, the 
proportion of dual users of snus and cigarettes has been quite small, and has not increased during the 
period when snus became more popular [24]. 
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Even if snus could be classified as neither a sufficient condition nor a necessary condition to reduce 
smoking in a given society, the experience from Norway indicates that snus should be considered as an 
important contributory factor in the decline of smoking. However, it is important to emphasize that the 
observed marked shift from cigarettes to snus in Norway could have been even stronger if 
misperceptions of the relative risk of the two products had been adjusted in accordance with medical 
consensus. Smokers [2,6,46] and even GPs [47] tend to overestimate the health risk from snus use 
compared with that from cigarette smoking, and among smokers who incorrectly perceive snus as 
being as risky as cigarettes, the willingness to try snus in an attempt to quit smoking is quite low [2]. 
Willingness to use snus in quit-smoking attempts is significantly higher for smokers who, consistent 
with scientific evidence, believe that the health risks are far lower for snus than for cigarettes [2]. 
Thus, dissemination of information from authorities to correct misconceptions of relative risk, as 
recommended by some US researchers [48], might speed up the trajectory from cigarettes to snus to 
quitting completely. 
Transfer Value to E-Cigarettes 
In Norway, snus has emerged as a realistic alternative to conventional cigarettes because of its 
ability to deliver nicotine without the combustion and the toxicants in tobacco smoke, the fact that snus 
can be used in smoke-free places, the competitive price and the perceived potential for harm reduction 
(even if this potential is under-estimated). The new snus products that were introduced to the nicotine 
market in the 1990s differed from conventional smokeless tobacco in that they were lower in major 
carcinogens such as tobacco-specific nitrosamines and polycyclic aromatic hydrocarbons [49,50], did 
not require spitting, came in a variety of flavours such as mint and eucalyptus, and were presented in 
small pouches packed in elegant and colourful tin boxes. These innovations certainly made snus more 
user-friendly and probably also increased its appeal, not only to established smokers, but also to young 
people with no prior history of tobacco use. However, snus samples from the US and India has been 
identified with nitrosamines as high as traditional moist snuff [51,52], so within the product category 
there are important variations. 
E-cigarettes share many of the above abilities to compete with cigarettes on the nicotine market 
(price, product variability, packaging, perceived harm reduction, identity formation and social and 
symbolic functions) [53]. Furthermore, e-cigarettes also offer some important advantages over snus. 
The repetitive hand-to-mouth motion, the visual cue of smoke-like vapour and the cigarette-like 
nicotine delivery device can maintain the behavioural component of smoking and the identity that 
many smokers appreciate. In markets where both products have access to the nicotine market,  
e-cigarettes have generally achieved higher popularity than snus [54]. Studies have also shown that 
smokers have reported a greater liking for e-cigarettes [55–57] than for snus [54,58,59]. Thus, the high 
receptivity towards snus in Scandinavia may not exist in other cultures. In the US current use of snus 
in women is almost non-existing and the potential impact on smoking cessation associated with snus 
use might not be replicable in the US [60]. 
On the other hand, many jurisdictions have recently banned or restricted indoor vaping, while the 
use of snus seems to remain more or less unregulated. Moreover, the customer base for e-cigarettes 
seems to be strictly limited to smokers, while snus has also had some appeal to a segment of  
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non-smokers, who comprise the majority of the population. However, e-cigarettes seem to appeal to 
both sexes, while snus use for the most part is observed among males. 
All in all, e-cigarettes possess most of the characteristics that made snus a significant competitor 
with cigarettes on the nicotine market in Norway. Moreover, e-cigarettes have unique behavioural and 
social functions beyond those of snus, resulting in higher popularity. Further, the customer base for  
e-cigarettes is not gender-specific (as it is for snus), and is therefore much larger. Consequently, at 
least in countries where the market conditions for e-cigarettes are similar to those for snus in Norway, 
the experience with snus may be replicated for e-cigarettes. Most probably, given their competitive 
advantages over snus, e-cigarettes would compete even better with cigarettes than snus when 
introduced to new markets. 
5. Limitations 
In principle, the contrasting of quit ratios for smoking between daily snus users and never snus 
users (Table 1), should be adjusted for variables known to influence smoking cessation. The results 
presented here are gender specific, and in some of the nine surveys restricted to specific age groups. 
However, length of education, risk perceptions and a full range of smoking behavior components (such 
as smoking intensity) are also predictors of successful smoking cessation attempts and thereby possible 
confounders. Several studies has shown that dual users of snus and cigarettes consume fewer cigarettes 
than do exclusive smokers [24], and that nicotine substitution with snus is the reason [21,23]. We had 
no information on cigarette consumption at the point in time where the smokers who later were to 
become dual users still was using cigarettes exclusively. Therefore, we were unable to adjust for 
smoking intensity. However, we have no evidence that low-intensity-daily-smokers are particularly 
attracted to snus (selection bias). 
6. Conclusions 
In Norway, snus has contributed to a decrease in cigarette consumption  through three mechanisms: 
(1) as a method of smoking cessation, (2) as an alternative product for new generations of  
tobacco-prone youth who otherwise would take up smoking, and (3) as an alternative to cigarettes for 
smokers who are unwilling or unable to quit smoking altogether. The availability of snus is neither a 
sufficient nor a necessary condition for a reduction in tobacco smoking. Tobacco control measures 
have perhaps been the most important factor in smoking reduction. However, in countries that already 
have a robust infrastructure for tobacco control, tobacco harm reduction strategies might be a 
necessary supplement to reduce smoking related mortality. Through the same mechanisms as with 
snus, e-cigarettes might appear as an important contributory factor towards a decrease in smoking. 
However, the effect would very much depend on how market access is regulated. 
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